✦ LIBER ✦

Clinical efficacy and safety of Flebogammadif®, a new high-purity human intravenous immunoglobulin, in adult patients with chronic idiopathic thrombocytopenic purpura

✍ Scribed by A. Julia; L. Kovaleva; S. Loria; I. Alberca; F. Hernandez; V. Sandoval; J. Sierra; A. Vidaller; J. Ayguasanosa; M. Carretero

Book ID: 110869220
Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 518 KB
Volume: 19
Category: Article
ISSN: 0958-7578
DOI: 10.1111/j.1365-3148.2009.00945.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and safety of a nanofiltered li

Efficacy and safety of a nanofiltered liquid intravenous immunoglobulin product in patients with primary immunodeficiency and idiopathic thrombocytopenic purpura

✍ J. W. M. van der Meer; R. T. van Beem; T. Robak; A. Deptala; P. F. W. Strengers 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 150 KB

Efficacy and safety of rituximab in adul

Efficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: Results of a Spanish multicenter study

✍ Javier de la Rubia; Federico Moscardó; María J Gómez; Ramón Guardia; Pilar Rodrí 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 181 KB

Safety and tolerability of a novel chrom

Safety and tolerability of a novel chromatography-based intravenous immunoglobulin when administered at a high infusion rate in patients with immune thrombocytopenic purpura

✍ James B. Bussel; Kim Hanna 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 153 KB 👁 2 views

## Abstract Intravenous immunoglobulin (IGIV) therapy is generally considered to be a safe and effective treatment for idiopathic thrombocytopenic purpura (ITP). The usual initial treatment dose is 1–2 g/kg body weight, which results in an extended infusion time, significantly impacting patients' d